Ligand Pharmaceuticals (LGND) Retained Earnings (2010 - 2026)

Ligand Pharmaceuticals (LGND) has 17 years of Retained Earnings data on file, last reported at $397.2 million in Q1 2026.

• For the quarter ending Q1 2026, Retained Earnings rose 25510.68% year-over-year to $397.2 million; the trailing twelve-month figure through Mar 2026 stood at $397.2 million (up 25510.68% YoY), and the FY2025 full-year result was $400.6 million, up 18.75% from the prior year.
• Retained Earnings fell to $397.2 million in Q1 2026, from $400.6 million in the prior quarter.
• In the past five years, Retained Earnings ranged from a high of $578.2 million in Q3 2025 to a low of -$1.6 million in Q1 2025.
• A 5-year average of $360.4 million and a median of $400.6 million in 2025 frame the typical range for Retained Earnings.
• Across the five-year window, Retained Earnings surged 39985.03% in 2022 and slumped 100.18% in 2024, its largest moves.
• Tracing LGND's Retained Earnings over 5 years: stood at $147.6 million in 2022, then surged by 240.82% to $503.0 million in 2023, then plunged by 32.93% to $337.4 million in 2024, then rose by 18.75% to $400.6 million in 2025, then dropped by 0.87% to $397.2 million in 2026.
• Business Quant data shows LGND's Retained Earnings at $397.2 million in Q1 2026, $400.6 million in Q4 2025, and $578.2 million in Q3 2025.